IP Library Granted Patent US 8,293,884
Granted Patent B2
US 8,293,884 · App. 11/796,731 · Granted Oct 23, 2012

Nucleic acid and amino acid sequences relating to

Assignee: Sanofi Pasteur Limited/Sanofi Pasteur Limitée
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,293,884
App. No.
11/796,731
Granted
Oct 23, 2012
Kind
B2
Abstract

The invention provides isolated polypeptide and nucleic acid sequences derived from Streptococcus pneumoniae that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.

Claims (49)

1. An isolated nucleic acid encoding a S. pneumoniae polypeptide comprising SEQ ID NO: 5326.

2. A recombinant expression vector comprising the nucleic acid of claim 1 operably linked to a transcription regulatory element.

3. A cell comprising the recombinant expression vector of claim 2 .

4. An isolated nucleic acid sequence selected from the group consisting of:

a) a nucleic acid encoding a S. pneumoniae polypeptide comprising SEQ ID NO: 5326;

b) a nucleic acid sequence fully complementary to a nucleic acid encoding a polypeptide comprising SEQ ID NO: 5326; and

c) an RNA of a) or b), wherein U is substituted for T.

5. A recombinant expression vector comprising the nucleic acid of claim 4 operably linked to a transcription regulatory element.

6. A cell comprising the recombinant expression vector of claim 5 .

7. An isolated nucleic acid encoding a S. pneumoniae polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 5326, wherein the polypeptide elicits an immune response against S. pneumoniae.

8. A recombinant expression vector comprising the nucleic acid of claim 7 operably linked to a transcription regulatory element.

9. A cell comprising the recombinant expression vector of claim 8 .

10. An isolated nucleic acid selected from the group consisting of:

a) a nucleic acid encoding a S. pneumoniae polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 5326;

b) a nucleic acid fully complementary to a nucleic acid encoding a polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 5326; and

c) an RNA of a) or b), wherein U is substituted for T,

wherein the polypeptide elicits an immune response against S. pneumoniae.

11. A recombinant expression vector comprising the nucleic acid of claim 10 operably linked to a transcription regulatory element.

12. A cell comprising the recombinant expression vector of claim 11 .

13. An isolated nucleic acid encoding a S. pneumoniae polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 5326, wherein the polypeptide provides immunity against S. pneumoniae infection.

14. A recombinant expression vector comprising the nucleic acid of claim 13 operably linked to a transcription regulatory element.

15. A cell comprising the recombinant expression vector of claim 14 .

16. An isolated nucleic acid selected from the group consisting of:

a) a nucleic acid encoding a S. pneumoniae polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 5326;

b) a nucleic acid fully complementary to a nucleic acid encoding a polypeptide having at least 80% identity to the amino acid sequence of SEQ ID NO: 5326; and

c) an RNA of a) or b), wherein U is substituted for T,

wherein the polypeptide provides immunity against S. pneumoniae infection.

17. A recombinant expression vector comprising the nucleic acid of claim 16 operably linked to a transcription regulatory element.

18. A cell comprising the recombinant expression vector of claim 17 .

19. The isolated nucleic acid of claim 7 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 90% identity to SEQ ID NO: 5326.

20. The isolated nucleic acid of claim 7 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 95% identity to SEQ ID NO: 5326.

21. The isolated nucleic acid of claim 7 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 98% identity to SEQ ID NO: 5326.

22. The isolated nucleic acid of claim 7 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 99% identity to SEQ ID NO: 5326.

23. The isolated nucleic acid of claim 13 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 90% identity to SEQ ID NO: 5326.

24. The isolated nucleic acid of claim 13 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 95% identity to SEQ ID NO: 5326.

25. The isolated nucleic acid of claim 13 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 98% identity to SEQ ID NO: 5326.

26. The isolated nucleic acid of claim 13 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 99% identity to SEQ ID NO: 5326.

27. The isolated nucleic acid of claim 10 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 90% identity to SEQ ID NO: 5326.

28. The isolated nucleic acid of claim 10 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 95% identity to SEQ ID NO: 5326.

29. The isolated nucleic acid of claim 10 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 98% identity to SEQ ID NO: 5326.

30. The isolated nucleic acid of claim 10 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 99% identity to SEQ ID NO: 5326.

31. The isolated nucleic acid of claim 16 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 90% identity to SEQ ID NO: 5326.

32. The isolated nucleic acid of claim 16 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 95% identity to SEQ ID NO: 5326.

33. The isolated nucleic acid of claim 16 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 98% identity to SEQ ID NO: 5326.

34. The isolated nucleic acid of claim 16 , wherein the nucleic acid encodes a S. pneumonaie polypeptide having at least 99% identity to SEQ ID NO: 5326.

35. The isolated nucleic acid of claim 7 , wherein the polypeptide is a surface protein.

36. The isolated nucleic acid of claim 10 , wherein the polypeptide is a surface protein.

37. The isolated nucleic acid of claim 13 , wherein the polypeptide is a surface protein.

38. The isolated nucleic acid of claim 16 , wherein the polypeptide is a surface protein.

Assignments (3)
CHANGE OF NAME Recorded Aug 6, 2012
From: AVENTIS PASTEUR LIMITED/AVENTIS PASTEUR LIMITEE
To: SANOFI PASTEUR LIMITED/SANOFI PASTEUR LIMITEE
Reel/Frame 028734/0586 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 2, 2012
From: GENOME THERAPEUTICS CORPORATION
To: AVENTIS PASTEUR LTD
Reel/Frame 028710/0522 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2012
From: DOUCETTE-STAMM, LYNN; BUSH, DAVID; ZENG, QIANDONG; OPPERMAN, TIMOTHY; HOUSEWEART, CHAD ERIC
To: GENOME THERAPEUTICS CORPORATION
Reel/Frame 028631/0522 →
Continuity (7)
Division 11028458 · Dec 30, 2004
Continuation 10640833 · Aug 14, 2003
Continuation 09583110 · May 26, 2000
Continuation In Part 09107433 · Jun 30, 1998
Provisional Application 60085131 · May 12, 1998
Provisional Application 60051553 · Jul 2, 1997
Related Publication 20080064083A1 · Mar 13, 2008